Skip Navigation
Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
AHRQ Home | Questions? | Contact Us | Site Map | What's New | Browse | Información en español | E-mail UpdatesE-mail Updates
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Search Results to Slide Tray Search:

"anthropometrics"

Slides: 1–7 of 7
Add to tray Remove from tray

Outcomes of Interest in Studies of rhGH Treatment of Patients With CF

Presentation: Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis
Keywords: intermediate outcomes | health outcomes | outcomes | pulmonary function | anthropometrics | bone mineralization | exercise tolerance | hospitalization rate | intravenous antibiotics | antibiotic use | health related quality of life | HRQoL | QoL | quality of life | bone consequences | mortality | cystic fibrosis | CF | rhGH | recombinant human growth hormone | human growth hormone | HGH
Add to tray Remove from tray

rhGH Effects on Intermediate Outcomes in Controlled Trials: Anthropometrics

Presentation: Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis
Keywords: BMI | CF | HGH | LBM | anthropometrics | body mass index | bone mineral content | cystic fibrosis | height | height Z-score | height velocity | human growth hormone | lean body mass | percent ideal body weight | recombinant human growth hormone | rhGH | weight | weight Z-score | weight velocity
Add to tray Remove from tray

Intermediate End Points and Health Outcomes in rhGH-Treated Patients With CF (1)

Presentation: Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis
Keywords: intermediate | outcome | end point | health outcome | mortality | health related quality of life | HRQoL | QoL | quality of life | cystic fibrosis | CF | rhGH | recombinant human growth hormone | human growth hormone | HGH
Add to tray Remove from tray

Intermediate End Points and Health Outcomes in rhGH-Treated Patients With CF (3)

Presentation: Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis
Keywords: regression | multivariate | univariate | anthropometrics | mortality | health related quality of life | HRQoL | QoL | quality of life | cystic fibrosis | CF | rhGH | recombinant human growth hormone | human growth hormone | HGH
Add to tray Remove from tray

Intermediate End Points and Health Outcomes in rhGH-Treated Patients With CF (4)

Presentation: Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis
Keywords: CF | HGH | HRQoL | QoL | anthropometrics | cystic fibrosis | health related quality of life | human growth hormone | mortality | multivariate | pulmonary function | quality of life | recombinant human growth hormone | regression | rhGH | univariate
Topic Refinement Process: UCONN/HH EPC Example (III). P—Patients with cystic fibrosis. I—Recombinant human growth hormone. C—Placebo, no therapy, another active therapy, or no control therapy. O—Pulmonary variables, anthropometrics, bone variables, IGF variables, hospitalization, bone fracture, health-related quality of life, glucose intolerance, malignancy, and mortality. T—At least 4 weeks of therapy with recombinant human growth hormone. S—Outpatient primary care, endocrine, or cystic fibrosis clinic.
Add to tray Remove from tray

Topic Refinement Process: UCONN/HH EPC Example (III)

Presentation: Topic Refinement
Keywords: topic refinement | method | intervention | PICOTS framework | inclusion criteria
Topic Refinement Process: UCONN/HH EPC Example (VII). Questions for Key Informants: How different is a study including people up to 23 years of age from a study limited to 18-year-olds? Consider this given the inverse linear relationship between human growth hormone efficacy and age, as well as the delayed growth and maturation inherent in this population. How readily do you feel we can combine certain end points (e.g., lean body mass measured by different methods [DEXA, skin folds, BIA] in same units) or amino acid catabolism measures (leucine vs. glutamine)?
Add to tray Remove from tray

Topic Refinement Process: UCONN/HH EPC Example (VII)

Presentation: Topic Refinement
Keywords: topic refinement | population | key informant
 
 
 
 
www.ahrq.gov AHRQ Home | Contact AHRQ | Site Map | Accessibility | Privacy Policy | Freedom of Information Act | Disclaimers
U.S. Department of Health & Human Services | The White House | USA.gov: The U.S. Government's Official Web Portal

Agency for Healthcare Research and Quality • 540 Gaither Road Rockville, MD 20850 • Telephone: (301) 427-1364